LANNETT CO INC

2023 Q2 Form 10-Q Financial Statement

#000155837023009852 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1

Balance Sheet

Concept 2023 Q2 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $46.54M
Short-Term Investments
Other Short-Term Assets $18.02M
YoY Change 12.94%
Inventory $90.81M
Prepaid Expenses
Receivables $68.15M
Other Receivables
Total Short-Term Assets $261.7M
YoY Change -17.88%
LONG-TERM ASSETS
Property, Plant & Equipment $12.36M
YoY Change -91.18%
Goodwill
YoY Change
Intangibles $18.91M
YoY Change -78.6%
Long-Term Investments
YoY Change
Other Assets $14.53M
YoY Change -3.82%
Total Long-Term Assets $72.91M
YoY Change -71.25%
TOTAL ASSETS
Total Short-Term Assets $261.7M
Total Long-Term Assets $72.91M
Total Assets $334.6M
YoY Change -41.53%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $21.07M
YoY Change -26.24%
Accrued Expenses $34.89M
YoY Change 119.81%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due $628.4M
YoY Change
Total Short-Term Liabilities $733.1M
YoY Change 676.94%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities $4.646M
YoY Change -72.5%
Total Long-Term Liabilities $4.646M
YoY Change -99.26%
TOTAL LIABILITIES
Total Short-Term Liabilities $733.1M
Total Long-Term Liabilities $4.646M
Total Liabilities $746.9M
YoY Change 2.09%
SHAREHOLDERS EQUITY
Retained Earnings -$762.2M
YoY Change 51.5%
Common Stock $368.7M
YoY Change 1.68%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$412.3M
YoY Change
Total Liabilities & Shareholders Equity $334.6M
YoY Change -41.53%

Cashflow Statement

Concept 2023 Q2 2023 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Security Exchange Name
SecurityExchangeName
NONE
dei Entity Central Index Key
EntityCentralIndexKey
0000057725
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2022Q1 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
CY2023Q1 us-gaap Restricted Cash Asset Statement Of Financial Position Extensible List
RestrictedCashAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent
lci Share Based Compensation Arrangement By Share Based Payment Award Service Based Clawback Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardServiceBasedClawbackPeriod
P36M
dei Entity File Number
EntityFileNumber
001-31298
lci Share Based Compensation Arrangement By Share Based Payment Award Clawback Annual Expiration Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardClawbackAnnualExpirationPercentage
0.33
CY2023Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.25
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
67000
dei Entity Registrant Name
EntityRegistrantName
LANNETT COMPANY, INC
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
23-0787699
dei Entity Address Address Line1
EntityAddressAddressLine1
1150 Northbrook Drive, Suite 155
dei Entity Address City Or Town
EntityAddressCityOrTown
Trevose
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19053
dei City Area Code
CityAreaCode
215
dei Local Phone Number
LocalPhoneNumber
333-9000
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
LCINQ (1)
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
10780187
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46540000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
87854000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
68153000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56241000
CY2023Q1 us-gaap Inventory Net
InventoryNet
90805000
CY2022Q2 us-gaap Inventory Net
InventoryNet
95158000
CY2022Q2 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
36793000
CY2023Q1 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
38200000
CY2023Q1 us-gaap Other Assets Current
OtherAssetsCurrent
18018000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
14070000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
261716000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
290116000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12363000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133178000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18907000
CY2022Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
32179000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9131000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9646000
CY2023Q1 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
17981000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14526000
CY2022Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
19316000
CY2023Q1 us-gaap Assets
Assets
334624000
CY2022Q2 us-gaap Assets
Assets
484435000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
21073000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
29737000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
34888000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
23667000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11918000
CY2022Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
8342000
CY2023Q1 lci Accrued Liabilities For Certain Rebate Programs Current
AccruedLiabilitiesForCertainRebateProgramsCurrent
13425000
CY2022Q2 lci Accrued Liabilities For Certain Rebate Programs Current
AccruedLiabilitiesForCertainRebateProgramsCurrent
21568000
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
8218000
CY2022Q2 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
5677000
CY2023Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
748000
CY2022Q2 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
490000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2079000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2064000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
628391000
CY2023Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
12339000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
13395000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
733079000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
104940000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
614948000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9158000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
9994000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4646000
CY2022Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5616000
CY2023Q1 us-gaap Liabilities
Liabilities
746883000
CY2022Q2 us-gaap Liabilities
Liabilities
735498000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
25000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11218213
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11168069
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10780272
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
10776603
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
11000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
11000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
368669000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
363988000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-762183000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-596386000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-384000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-411000
CY2023Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
437941
CY2022Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
391466
CY2023Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
18372000
CY2022Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
18265000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-412259000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-251063000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
334624000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
484435000
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80507000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78357000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236480000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
266390000
CY2023Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
64289000
CY2022Q1 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
72658000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
190832000
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
230656000
CY2023Q1 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
1043000
CY2022Q1 us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
2621000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
3596000
us-gaap Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
10425000
CY2023Q1 us-gaap Gross Profit
GrossProfit
15175000
CY2022Q1 us-gaap Gross Profit
GrossProfit
3078000
us-gaap Gross Profit
GrossProfit
42052000
us-gaap Gross Profit
GrossProfit
25309000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7105000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5807000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19212000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16318000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20446000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17572000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
55460000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
55268000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
1795000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
1782000
us-gaap Restructuring Charges
RestructuringCharges
2276000
us-gaap Restructuring Charges
RestructuringCharges
2673000
CY2023Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
72510000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
83147000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
49361000
us-gaap Gain Loss On Disposition Of Intangible Assets
GainLossOnDispositionOfIntangibleAssets
3563000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
101856000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
25161000
us-gaap Operating Expenses
OperatingExpenses
156532000
us-gaap Operating Expenses
OperatingExpenses
123620000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-86681000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-22083000
us-gaap Operating Income Loss
OperatingIncomeLoss
-114480000
us-gaap Operating Income Loss
OperatingIncomeLoss
-98311000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
83000
CY2022Q1 us-gaap Investment Income Net
InvestmentIncomeNet
34000
us-gaap Investment Income Net
InvestmentIncomeNet
574000
us-gaap Investment Income Net
InvestmentIncomeNet
114000
CY2023Q1 us-gaap Interest Expense
InterestExpense
15179000
CY2022Q1 us-gaap Interest Expense
InterestExpense
14517000
us-gaap Interest Expense
InterestExpense
45393000
us-gaap Interest Expense
InterestExpense
43171000
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
6826000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
336000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
303000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
423000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
252000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14760000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1475000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-14180000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-51222000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42805000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101441000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-36263000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-165702000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-141116000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1365000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
95000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2791000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101470000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34898000
us-gaap Net Income Loss
NetIncomeLoss
-165797000
us-gaap Net Income Loss
NetIncomeLoss
-138325000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.84
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.74
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.84
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.45
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.74
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10311428
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10125825
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10279085
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10065333
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10311428
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10125825
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10279085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10065333
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101470000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34898000
us-gaap Net Income Loss
NetIncomeLoss
-165797000
us-gaap Net Income Loss
NetIncomeLoss
-138325000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-17000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
-7000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
27000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Before Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
22000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-101487000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34905000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-165770000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-138303000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-312274000
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
28000
CY2023Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-17000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101470000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-412259000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-126160000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1699000
CY2022Q1 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
9000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-7000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34898000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-159308000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-251063000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
95000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4586000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
107000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
27000
us-gaap Net Income Loss
NetIncomeLoss
-165797000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-412259000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-27471000
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
267000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7026000
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
827000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
22000
us-gaap Net Income Loss
NetIncomeLoss
-138325000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-159308000
us-gaap Profit Loss
ProfitLoss
-165797000
us-gaap Profit Loss
ProfitLoss
-138325000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
19333000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26659000
us-gaap Share Based Compensation
ShareBasedCompensation
4586000
us-gaap Share Based Compensation
ShareBasedCompensation
7026000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
83147000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
49361000
us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
6826000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
3563000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
279000
us-gaap Paid In Kind Interest
PaidInKindInterest
8171000
us-gaap Paid In Kind Interest
PaidInKindInterest
15115000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
5542000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
4553000
us-gaap Inventory Write Down
InventoryWriteDown
4068000
us-gaap Inventory Write Down
InventoryWriteDown
11427000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-673000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-628000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11912000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-34860000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-285000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2684000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
18894000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-2194000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
6244000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
561000
lci Increase Decrease In Rebates Chargebacks And Returns Payable
IncreaseDecreaseInRebatesChargebacksAndReturnsPayable
-8143000
lci Increase Decrease In Rebates Chargebacks And Returns Payable
IncreaseDecreaseInRebatesChargebacksAndReturnsPayable
5307000
lci Increase Decrease In Royalty Payable
IncreaseDecreaseInRoyaltyPayable
2541000
lci Increase Decrease In Royalty Payable
IncreaseDecreaseInRoyaltyPayable
-7634000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
258000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
891000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-989000
us-gaap Depreciation
Depreciation
15700000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-835000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-8664000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1014000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
11071000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2795000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
3576000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
137000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-2108000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
1284000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-38449000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11885000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6580000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9260000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
4700000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
12235000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1000000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1500000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2880000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1475000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
95000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
267000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
107000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
827000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-12000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-560000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
27000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-41314000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
12822000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
92854000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
98286000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51540000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111108000
us-gaap Interest Paid Net
InterestPaidNet
23993000
us-gaap Interest Paid Net
InterestPaidNet
17155000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-18798000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-596000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
53000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1096000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
5000000.0
us-gaap Nature Of Operations
NatureOfOperations
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Note 2. The Business and Nature of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Lannett Company, Inc., a Delaware corporation, (“LCI,” and as it may be reorganized pursuant to the Prepackaged Plan (as defined below), “Reorganized LCI”) and its subsidiaries (collectively, the “Company,” “Lannett, ” “we” or “us” and as it may be reorganized pursuant to the Prepackaged Plan, the “Reorganized Company” ) primarily develop, manufacture, package, market and distribute solid oral and extended release (tablets and capsules), topical, nasal and oral solution finished dosage forms of drugs that address a wide range of therapeutic areas. Certain of these products are manufactured by others and distributed by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company operates a pharmaceutical manufacturing plant in Seymour, Indiana. During Fiscal 2022, the Company completed the sale of its Silarx Pharmaceuticals, Inc. (“Silarx”) facility in Carmel, New York. In connection with the sale, the buyer will continue to produce certain products on behalf of the Company at the Carmel facility while the Company completes the transfer of such products to its Seymour, Indiana plant. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The Company’s customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities and health maintenance organizations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Going Concern</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our interim unaudited consolidated financial statements included herein have been prepared using the going concern basis of accounting, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the normal course of business. In accordance with ASC 205, <i style="font-style:italic;">Going Concern</i>, the Company evaluated whether there are any conditions or events, considered in the aggregate, that raise substantial doubt about our ability to continue as a going concern within one year beyond the filing of this Quarterly Report on Form 10-Q. As a result of our evaluation, we concluded that substantial doubt exists regarding our ability to continue as a going concern primarily as a result of the risks and uncertainties related to the Prepackaged Plan and Chapter 11 Cases, which are both defined and discussed further in this Quarterly Report on Form 10-Q. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 4, 2023 and April 17, 2023, the Company elected to defer interest payments on the Company’s 4.50% Convertible Senior Notes (the “Convertible Notes”) and the Company’s 7.750% Senior Secured Notes due 2026 (the “Secured Notes” and, together with the Convertible Notes, the “Notes”), respectively, and, in each case, enter a 30-day grace period. Failure to make an interest payment within the 30-day grace period constitutes an event of default under the Indenture, dated as of September 27, 2019 (the “Convertible Notes Indenture”), between the Company and Wilmington Trust, National Association, as trustee, and the Indenture, dated April 22, 2021, as supplemented by the first supplemental indenture, dated April 22, 2021(the “Secured Notes Indenture”), among the Company, the subsidiary guarantors party thereto and Wilmington Trust, National Association, as trustee and note collateral agent. Because the 30-day grace period has elapsed, an event of default occurred with respect to the Convertible Notes. As such, the trustee or the holders of at least 25% in aggregate principal amount of the outstanding Convertible Notes may declare 100% of the principal of, and accrued and unpaid interest on, all the Convertible Notes to be due and payable immediately. With respect to the Secured Notes, as a result of the event of default, the trustee or the holders of not less than 30% in aggregate principal amount of the outstanding Secured Notes may declare 100% of the principal of, and accrued and unpaid interest on, the Secured Notes to be due and payable immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Additionally, on April 24, 2023, the Company elected to defer an interest payment (together with the missed interest payments on the Notes, the “Missed Interest Payments”) in respect of its second lien credit and guaranty agreement, dated April 22, 2021 (the “Second Lien Credit Agreement”), by and among the Company, the other credit parties party thereto, the lenders party thereto and Alter Domus (US) LLC, as administrative agent and collateral agent, pursuant to which lenders party thereto made available to the Company a second lien term loan credit facility (the “Second Lien Credit Facility”). The Company did not make the interest payment within the ten-business day grace period (such grace period having been extended pursuant to the Restructuring Support Agreement, as defined below), which constituted an event of default under the Second Lien Credit Facility. Upon an event of default, the administrative agent, itself or at the request of requisite lenders, may declare the Second Lien Credit Facility and interest thereon due and payable and exercise all rights and remedies under the Second Lien Credit Facility and related agreements. The Company’s failure to pay the interest on the Second Lien Credit Facility by the end of the grace period also constituted an event of default under the Convertible Notes Indenture, the Secured Notes Indenture and the Company’s Credit and Guaranty Agreement, dated as of December 7, 2020 (as amended, the “Amended ABL Credit Agreement”), among the Company, certain of its wholly-owned domestic subsidiaries party thereto, as borrowers or as guarantors, Wells Fargo Bank, National Association, as administrative agent and as collateral agent and the other lenders party thereto.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">On April 19, 2023, the Company received written notice from the New York Stock Exchange (the “NYSE”) notifying the Company that the NYSE had commenced proceedings to delist the Company’s common stock. The NYSE reached this determination pursuant to Section 802.01(B) of the NYSE’s Listed Company Manual because the Company had fallen below the NYSE’s continued listing standard requiring listed companies to maintain an average global market capitalization of at least $15.0 million over a consecutive 30 trading-day period. The NYSE suspended trading in the Company’s common stock immediately after market close on April 19, 2023, and on April 20, 2023, the Company’s common stock began trading in the over-the-counter markets under the symbol “LCIN.” After the filing of the Chapter 11 Cases (as defined below), on May 3, 2023, our common stock began trading in the over-the-counter markets under the symbol “LCINQ.” On May 4, 2023, the NYSE filed a Form 25 with the Securities and Exchange Commission (the “SEC”) to delist our common stock from trading on the NYSE and to remove it from registration under Section 12(b) of the Exchange Act. The delisting of the Company’s common stock (the “Delisting”) became effective 10 days after the filing of the Form 25. In accordance with Rule 12d2-2 of the Exchange Act, the de-registration of our common stock under Section 12(b) of the Exchange Act will become effective 90 days, or such shorter period as the SEC may determine, after the date of the Form 25 filing.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the Convertible Notes Indenture, the Delisting constituted a Fundamental Change (as defined therein). Upon the occurrence of a Fundamental Change, the Company must provide all holders of Convertible Notes and the trustee a notice (the “Fundamental Change Company Notice”) of the occurrence of the Fundamental Change and of the holder’s option to require the Company to repurchase for cash all of such holder’s notes at 100% of the principal amount, plus accrued and unpaid interest. Failure by the Company to issue a Fundamental Change Company Notice within 20 days following the fundamental change constitutes an event of default and, if the trustee or holders of at least 25% in aggregate principal amount of the Convertible Notes declared 100% of the principal of, and accrued and unpaid interest on, all the Notes to be due and payable immediately, the Convertible Notes would become immediately due and payable. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">If holders were to exercise their option to accelerate the maturity of either series of the Notes, it would also constitute an event of default under the other series of Notes, as well as the Second Lien Credit Facility and the Amended ABL Credit Agreement. Similarly, if the Second Lien Credit Facility administrative agent, itself or at the request of requisite lenders, exercises its option to accelerate the maturity of the Second Lien Credit Facility, it would also constitute an event of default under the Notes and the Amended ABL Credit Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">On April 30, 2023, Lannett Company, Inc., Kremers Urban Pharmaceuticals, Inc., Cody Laboratories, Inc. and Silarx Pharmaceuticals, Inc. (collectively, the “Company Parties”) and certain of the Company’s debtholders (the “Consenting Stakeholders”) entered into the restructuring support agreement (the “Restructuring Support Agreement”) to facilitate the financial restructuring (the “Restructuring”) of the existing debt of, existing equity interests in and certain other obligations of the Company Parties. In connection therewith, on May 2, 2023 (the “Petition Date”), the Company Parties commenced cases (the “Chapter 11 Cases”) under chapter 11 (“Chapter 11”) of title 11 of the United States Code (the “Bankruptcy Code”) in the Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). On May 2, 2023, the Company Parties filed the Joint Prepackaged Chapter 11 Plan of Reorganization of Lannett Company, Inc. and Its Debtor Affiliates (the “Prepackaged Plan”). Each Company Party will continue to operate its business as a “debtor in possession” under the jurisdiction of the Bankruptcy Court and in accordance with the applicable provisions of the Bankruptcy Code and the orders of the Bankruptcy Court. The Chapter 11 Cases are being jointly administered under the caption <i style="font-style:italic;">In re Lannett Company, Inc., et al., </i>Case No. 23-10559 (JKS). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The filing of the Chapter 11 Cases constituted an event of default that accelerated all of our debt obligations under the Convertible Notes Indenture, the Secured Notes Indenture, the Second Lien Credit Agreement and the Amended ABL Credit Agreement. As such, we have reclassified all debt obligations to debt due within a year on our Consolidated Balance Sheet as of March 31, 2023. Our consolidated interim unaudited financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. For additional discussion related to the impact of the Chapter 11 Cases on our debt obligations, see Note 10 “Debt.” For additional information related to the effect of the automatic stay on actions to collect indebtedness incurred prior to the Petition Date or to exercise control over the Company Parties’ property, see Note 11 “Legal, Regulatory Matters and Contingencies” and Note 20 “Subsequent Events.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Our ability to continue as a going concern is contingent upon, among other things, our ability to, subject to the Bankruptcy Court’s approval, implement the Prepackaged Plan, successfully emerge from the Chapter 11 Cases and establish a sustainable capital structure through the Restructuring. As a result of risks and uncertainties related to the Missed Interest Payments, the Delisting and the effects of disruption from the Chapter 11 Cases making it more difficult to maintain business, financing and operational relationships, together with the Company’s recurring losses from operations and accumulated deficit, substantial doubt exists regarding our ability to continue as a going concern. For detailed discussion about the Restructuring Support Agreement and the Prepackaged Plan, see Note 20 “Subsequent Events.”</p>
CY2023Q2 us-gaap Bankruptcy Proceedings Date Petitions For Bankruptcy Filed
BankruptcyProceedingsDatePetitionsForBankruptcyFiled
2023-05-02
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reclassifications </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Certain prior year amounts have been reclassified to conform to the current year financial statement presentation.</p>
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Splits
StockIssuedDuringPeriodSharesStockSplits
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions are required in the determination of revenue recognition and sales deductions for estimated chargebacks, rebates, returns and other adjustments including a provision for the Company’s liability under the Medicare Part D program. Additionally, significant estimates and assumptions are required when determining the value of inventories and long-lived assets, including intangible assets, income taxes, and contingencies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">Because of the inherent subjectivity and complexity involved in these estimates and assumptions, actual results could differ from those estimates.</p>
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46540000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
106108000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
5000000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
5000000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51540000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
111108000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
80507000
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
78357000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
236480000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
266390000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Product and customer concentration</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">For the three and nine months ended March 31, 2023 and 2022, the Company did not have any products, defined as containing the same active ingredient or combination of ingredients, that accounted for at least 10% of total net sales. </p><p style="font-family:'Courier New';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The following table presents the percentage of total net sales, for the three and nine months ended March 31, 2023 and 2022, for certain of the Company’s customers which accounted for at least 10% of total net sales in any of those periods:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#0563c1;font-size:8pt;font-weight:bold;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:16.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td></tr><tr><td style="vertical-align:bottom;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer A</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:58.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer B</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 19</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:58.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Customer C</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 14</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p>
CY2023Q1 us-gaap Self Insurance Reserve
SelfInsuranceReserve
1200000
CY2022Q2 us-gaap Self Insurance Reserve
SelfInsuranceReserve
500000
CY2023Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
180873000
CY2022Q2 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
199242000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
949000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
984000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
68153000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
56241000
CY2022Q2 lci Rebates Chargebacks And Returns Payable
RebatesChargebacksAndReturnsPayable
163585000
lci Chargebacks Rebates Returns And Other Reserves Provision
ChargebacksRebatesReturnsAndOtherReservesProvision
386747000
lci Chargebacks Rebates Returns And Other Reserves Credits Issued
ChargebacksRebatesReturnsAndOtherReservesCreditsIssued
425136000
CY2023Q1 lci Rebates Chargebacks And Returns Payable
RebatesChargebacksAndReturnsPayable
125196000
CY2021Q2 lci Rebates Chargebacks And Returns Payable
RebatesChargebacksAndReturnsPayable
158761000
lci Chargebacks Rebates Returns And Other Reserves Provision
ChargebacksRebatesReturnsAndOtherReservesProvision
481619000
lci Chargebacks Rebates Returns And Other Reserves Credits Issued
ChargebacksRebatesReturnsAndOtherReservesCreditsIssued
478983000
CY2022Q1 lci Rebates Chargebacks And Returns Payable
RebatesChargebacksAndReturnsPayable
161397000
CY2022Q1 us-gaap Depreciation
Depreciation
5200000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
39754000
CY2022Q2 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
39297000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
11759000
CY2022Q2 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
9313000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
39292000
CY2022Q2 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
46548000
CY2023Q1 us-gaap Inventory Net
InventoryNet
90805000
CY2022Q2 us-gaap Inventory Net
InventoryNet
95158000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
800000
CY2022Q1 us-gaap Inventory Write Down
InventoryWriteDown
7400000
us-gaap Inventory Write Down
InventoryWriteDown
4100000
us-gaap Inventory Write Down
InventoryWriteDown
11400000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
54077000
CY2022Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
136433000
CY2023Q1 lci Property Plant And Equipment Net Excluding Construction In Progress
PropertyPlantAndEquipmentNetExcludingConstructionInProgress
9778000
CY2022Q2 lci Property Plant And Equipment Net Excluding Construction In Progress
PropertyPlantAndEquipmentNetExcludingConstructionInProgress
120022000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
12363000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
133178000
CY2023Q1 us-gaap Depreciation
Depreciation
5800000
us-gaap Depreciation
Depreciation
16200000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
38693000
CY2022Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
58162000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
19786000
CY2022Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
25983000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18907000
CY2022Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
32179000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
3600000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
10400000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
727000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
2607000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
2573000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2406000
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
2269000
CY2023Q1 lci Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
8325000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18907000
CY2023Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
628391000
CY2022Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
614948000
CY2023Q1 us-gaap Long Term Debt Weighted Average Interest Rate Over Time
LongTermDebtWeightedAverageInterestRateOverTime
0.093
CY2022Q1 us-gaap Long Term Debt Weighted Average Interest Rate Over Time
LongTermDebtWeightedAverageInterestRateOverTime
0.091
us-gaap Long Term Debt Weighted Average Interest Rate Over Time
LongTermDebtWeightedAverageInterestRateOverTime
0.092
us-gaap Long Term Debt Weighted Average Interest Rate Over Time
LongTermDebtWeightedAverageInterestRateOverTime
0.089
CY2023Q1 us-gaap Interest Payable Current
InterestPayableCurrent
16600000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9100000
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9600000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11200000
CY2022Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
12100000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2100000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
456000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
456000
us-gaap Operating Lease Cost
OperatingLeaseCost
1388000
us-gaap Operating Lease Cost
OperatingLeaseCost
1361000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
61000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
63000
us-gaap Variable Lease Cost
VariableLeaseCost
140000
us-gaap Variable Lease Cost
VariableLeaseCost
120000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
95000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
101000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
323000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
253000
CY2023Q1 us-gaap Lease Cost
LeaseCost
612000
CY2022Q1 us-gaap Lease Cost
LeaseCost
620000
us-gaap Lease Cost
LeaseCost
1851000
us-gaap Lease Cost
LeaseCost
1734000
us-gaap Operating Lease Payments
OperatingLeasePayments
1608000
us-gaap Operating Lease Payments
OperatingLeasePayments
1606000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.085
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
537000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2083000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2103000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2124000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2145000
CY2023Q1 lci Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
6368000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
15360000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
4123000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
11237000
CY2017 us-gaap Loans And Leases Receivable Commitments Fixed Rates
LoansAndLeasesReceivableCommitmentsFixedRates
15000000.0
CY2017 lci Loans Receivable Fixed Rate
LoansReceivableFixedRate
0.020
CY2017 lci Loans And Leases Receivable Term
LoansAndLeasesReceivableTerm
P7Y
CY2022Q4 us-gaap Provision For Loan Losses Expensed
ProvisionForLoanLossesExpensed
6800000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-101470000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-34898000
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-101470000
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-34898000
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10311428
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10125825
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10311428
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10125825
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.84
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.45
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.84
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.45
us-gaap Net Income Loss
NetIncomeLoss
-165797000
us-gaap Net Income Loss
NetIncomeLoss
-138325000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-165797000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-138325000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10279085
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
10065333
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10279085
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
10065333
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-13.74
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-13.74
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1800000
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000000.0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1800000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2000000.0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
2000000.0
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
393000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
3800000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2022Q4 us-gaap Employee Service Share Based Compensation Cash Flow Effect Cash Used To Settle Awards
EmployeeServiceShareBasedCompensationCashFlowEffectCashUsedToSettleAwards
1300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P3Y
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1475000
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1699000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4586000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7026000
CY2023Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
332000
CY2022Q1 us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
382000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
1032000
us-gaap Employee Service Share Based Compensation Tax Benefit From Compensation Expense
EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
1581000
CY2020Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
0.50
CY2020Q4 us-gaap Defined Contribution Plan Employer Matching Contribution Percent
DefinedContributionPlanEmployerMatchingContributionPercent
0.04
CY2023Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
400000
CY2022Q1 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
300000
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000.0
us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
800000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
29000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1400000
CY2023Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.038
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
95000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2800000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.001
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.020
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4600000
CY2022Q2 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
4600000
CY2023Q1 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4500000
CY2022Q2 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4500000
CY2023Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2022Q2 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
lci-20230331_lab.xml Edgar Link unprocessable
0001558370-23-009852-index-headers.html Edgar Link pending
0001558370-23-009852-index.html Edgar Link pending
0001558370-23-009852.txt Edgar Link pending
0001558370-23-009852-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lci-20230331.xsd Edgar Link pending
lci-20230331x10q.htm Edgar Link pending
lci-20230331xex31d1.htm Edgar Link pending
lci-20230331xex31d2.htm Edgar Link pending
lci-20230331xex32.htm Edgar Link pending
lci-20230331xex3d9.htm Edgar Link pending
lci-20230331xex3d9001.jpg Edgar Link pending
lci-20230331xex3d9002.jpg Edgar Link pending
lci-20230331xex3d9003.jpg Edgar Link pending
lci-20230331xex3d9005.jpg Edgar Link pending
lci-20230331xex3d9006.jpg Edgar Link pending
lci-20230331xex3d9007.jpg Edgar Link pending
lci-20230331xex3d9008.jpg Edgar Link pending
lci-20230331xex3d9009.jpg Edgar Link pending
lci-20230331xex3d9010.jpg Edgar Link pending
lci-20230331xex3d9011.jpg Edgar Link pending
lci-20230331xex3d9012.jpg Edgar Link pending
lci-20230331xex3d9014.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
lci-20230331_cal.xml Edgar Link unprocessable
lci-20230331_def.xml Edgar Link unprocessable
lci-20230331x10q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
lci-20230331_pre.xml Edgar Link unprocessable